IL101046A - Amidazotri-azolequinazoline compounds are converted, their preparation and their pharmaceutical preparations - Google Patents
Amidazotri-azolequinazoline compounds are converted, their preparation and their pharmaceutical preparationsInfo
- Publication number
- IL101046A IL101046A IL10104692A IL10104692A IL101046A IL 101046 A IL101046 A IL 101046A IL 10104692 A IL10104692 A IL 10104692A IL 10104692 A IL10104692 A IL 10104692A IL 101046 A IL101046 A IL 101046A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- defined above
- reacting
- general formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 73
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title abstract description 4
- -1 aralkoxy Chemical group 0.000 claims abstract description 13
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 125000003277 amino group Chemical group 0.000 claims abstract description 3
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 3
- 150000001721 carbon Chemical group 0.000 claims abstract description 3
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 14
- 210000003169 central nervous system Anatomy 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- ZBIAFNABYZOHCJ-UHFFFAOYSA-N [1,2,4]triazolo[1,5-c]quinazoline Chemical compound C12=CC=CC=C2N=CN2C1=NC=N2 ZBIAFNABYZOHCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000012024 dehydrating agents Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 abstract description 4
- 125000000217 alkyl group Chemical group 0.000 abstract description 4
- 239000001961 anticonvulsive agent Substances 0.000 abstract description 4
- 230000000949 anxiolytic effect Effects 0.000 abstract description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002249 anxiolytic agent Substances 0.000 abstract description 3
- 229940049706 benzodiazepine Drugs 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 3
- 230000000147 hypnotic effect Effects 0.000 abstract description 3
- 230000003474 anti-emetic effect Effects 0.000 abstract description 2
- 229940125681 anticonvulsant agent Drugs 0.000 abstract description 2
- 229940125683 antiemetic agent Drugs 0.000 abstract description 2
- 239000002111 antiemetic agent Substances 0.000 abstract description 2
- 239000000164 antipsychotic agent Substances 0.000 abstract description 2
- 229940005529 antipsychotics Drugs 0.000 abstract description 2
- 229940005530 anxiolytics Drugs 0.000 abstract description 2
- 230000003920 cognitive function Effects 0.000 abstract description 2
- 239000003326 hypnotic agent Substances 0.000 abstract description 2
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 9
- BGHGVAKKIBOJGS-UHFFFAOYSA-N 5-cyclopropyl-3-(isocyanomethyl)-1,2,4-oxadiazole Chemical compound [C-]#[N+]CC1=NOC(C2CC2)=N1 BGHGVAKKIBOJGS-UHFFFAOYSA-N 0.000 description 6
- 102000004300 GABA-A Receptors Human genes 0.000 description 5
- 108090000839 GABA-A Receptors Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KFVVSDPKGPUSEL-UHFFFAOYSA-N 3-cyclopropyl-5-(isocyanomethyl)-1,2,4-oxadiazole Chemical compound O1C(C[N+]#[C-])=NC(C2CC2)=N1 KFVVSDPKGPUSEL-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229960002200 flunitrazepam Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical class N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
- LUFJSIPNMUKBNP-UHFFFAOYSA-N 3-(isocyanomethyl)-1,2-oxazole Chemical class [C-]#[N+]CC=1C=CON=1 LUFJSIPNMUKBNP-UHFFFAOYSA-N 0.000 description 1
- SOQRUSKLCUIAOJ-UHFFFAOYSA-N 4-(isocyanomethyl)oxadiazole Chemical class [C-]#[N+]CC1=CON=N1 SOQRUSKLCUIAOJ-UHFFFAOYSA-N 0.000 description 1
- AYADYLXXJHIYGA-UHFFFAOYSA-N 5,10-dichloro-2-methyl-[1,2,4]triazolo[1,5-c]quinazoline Chemical compound C12=C(Cl)C=CC=C2N=C(Cl)N2C1=NC(C)=N2 AYADYLXXJHIYGA-UHFFFAOYSA-N 0.000 description 1
- IZQOPXFKRIDKPG-UHFFFAOYSA-N 5,10-dichloro-[1,2,4]triazolo[1,5-c]quinazoline Chemical compound N1=C(Cl)N2N=CN=C2C2=C1C=CC=C2Cl IZQOPXFKRIDKPG-UHFFFAOYSA-N 0.000 description 1
- RQJMFMOXANUKBK-UHFFFAOYSA-N 5-chloro-9-methyl-[1,2,4]triazolo[1,5-c]quinazoline Chemical compound N1=C(Cl)N2N=CN=C2C2=CC(C)=CC=C21 RQJMFMOXANUKBK-UHFFFAOYSA-N 0.000 description 1
- AMCSZZBPTPRISD-UHFFFAOYSA-N 5-chloro-[1,2,4]triazolo[1,5-c]quinazoline Chemical compound C1=CC=C2C3=NC=NN3C(Cl)=NC2=C1 AMCSZZBPTPRISD-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- TYAMZJJUGLZDQQ-UHFFFAOYSA-N [1,2,4]triazolo[4,3-c]quinazoline Chemical compound C1=CC=C2N=CN3C=NN=C3C2=C1 TYAMZJJUGLZDQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- YXPSHYSNBMFNEC-UHFFFAOYSA-N triazolo[1,5-c]quinazoline Chemical compound C1=CC=C2C3=CN=NN3C=NC2=C1 YXPSHYSNBMFNEC-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Lubricants (AREA)
- Eye Examination Apparatus (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK91411A DK41191D0 (da) | 1991-03-07 | 1991-03-07 | Heterocycliske forbindelser, deres fremstilling og anvendelse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL101046A0 IL101046A0 (en) | 1992-11-15 |
| IL101046A true IL101046A (en) | 1995-10-31 |
Family
ID=8093215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10104692A IL101046A (en) | 1991-03-07 | 1992-02-24 | Amidazotri-azolequinazoline compounds are converted, their preparation and their pharmaceutical preparations |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5260298A (fr) |
| EP (1) | EP0575442B1 (fr) |
| JP (1) | JPH0813818B2 (fr) |
| AT (1) | ATE132151T1 (fr) |
| AU (1) | AU650733B2 (fr) |
| CA (1) | CA2105675A1 (fr) |
| DE (1) | DE69207180T2 (fr) |
| DK (2) | DK41191D0 (fr) |
| ES (1) | ES2082458T3 (fr) |
| FI (1) | FI933878A (fr) |
| GR (1) | GR3018896T3 (fr) |
| IE (1) | IE920644A1 (fr) |
| IL (1) | IL101046A (fr) |
| NO (1) | NO933162D0 (fr) |
| NZ (1) | NZ241846A (fr) |
| PT (1) | PT100204A (fr) |
| WO (1) | WO1992015591A1 (fr) |
| ZA (1) | ZA921649B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201311B (fr) * | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| AU4035893A (en) * | 1991-12-17 | 1993-07-19 | Upjohn Company, The | 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity |
| AU6470096A (en) * | 1995-07-19 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused triazole compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK476885D0 (da) * | 1985-10-17 | 1985-10-17 | Ferrosan As | Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf |
| DK443589D0 (da) * | 1989-09-08 | 1989-09-08 | Ferrosan As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
-
1991
- 1991-03-07 DK DK91411A patent/DK41191D0/da not_active Application Discontinuation
-
1992
- 1992-02-19 DK DK92906903.7T patent/DK0575442T3/da active
- 1992-02-19 WO PCT/DK1992/000050 patent/WO1992015591A1/fr active IP Right Grant
- 1992-02-19 DE DE69207180T patent/DE69207180T2/de not_active Expired - Fee Related
- 1992-02-19 EP EP92906903A patent/EP0575442B1/fr not_active Expired - Lifetime
- 1992-02-19 CA CA002105675A patent/CA2105675A1/fr not_active Abandoned
- 1992-02-19 AT AT92906903T patent/ATE132151T1/de not_active IP Right Cessation
- 1992-02-19 ES ES92906903T patent/ES2082458T3/es not_active Expired - Lifetime
- 1992-02-19 AU AU14148/92A patent/AU650733B2/en not_active Ceased
- 1992-02-19 JP JP4506489A patent/JPH0813818B2/ja not_active Expired - Lifetime
- 1992-02-20 US US07/839,981 patent/US5260298A/en not_active Expired - Fee Related
- 1992-02-24 IL IL10104692A patent/IL101046A/en not_active IP Right Cessation
- 1992-02-28 IE IE064492A patent/IE920644A1/en not_active Application Discontinuation
- 1992-03-05 ZA ZA921649A patent/ZA921649B/xx unknown
- 1992-03-05 NZ NZ241846A patent/NZ241846A/xx unknown
- 1992-03-06 PT PT100204A patent/PT100204A/pt not_active Application Discontinuation
-
1993
- 1993-09-06 NO NO933162A patent/NO933162D0/no unknown
- 1993-09-06 FI FI933878A patent/FI933878A/fi not_active Application Discontinuation
-
1996
- 1996-02-01 GR GR960400293T patent/GR3018896T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2105675A1 (fr) | 1992-09-08 |
| ATE132151T1 (de) | 1996-01-15 |
| FI933878A0 (fi) | 1993-09-06 |
| ES2082458T3 (es) | 1996-03-16 |
| DK0575442T3 (da) | 1996-05-06 |
| EP0575442B1 (fr) | 1995-12-27 |
| AU1414892A (en) | 1992-10-06 |
| EP0575442A1 (fr) | 1993-12-29 |
| NZ241846A (en) | 1993-10-26 |
| DE69207180T2 (de) | 1996-06-05 |
| JPH0813818B2 (ja) | 1996-02-14 |
| NO933162D0 (no) | 1993-09-06 |
| US5260298A (en) | 1993-11-09 |
| DE69207180D1 (de) | 1996-02-08 |
| IE920644A1 (en) | 1992-09-09 |
| JPH06501488A (ja) | 1994-02-17 |
| DK41191D0 (da) | 1991-03-07 |
| ZA921649B (en) | 1992-11-25 |
| GR3018896T3 (en) | 1996-05-31 |
| PT100204A (pt) | 1993-05-31 |
| IL101046A0 (en) | 1992-11-15 |
| FI933878A (fi) | 1993-09-06 |
| WO1992015591A1 (fr) | 1992-09-17 |
| AU650733B2 (en) | 1994-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0225013B1 (fr) | Composés hétérocycliques, leur préparation et leur utiisation | |
| EP0241682B1 (fr) | Dérivés de benzodiazépine et leur préparation et utilisation | |
| EP0226282B1 (fr) | Composés hétérocycliques, leur préparation et leur utilisation | |
| EP0347094B1 (fr) | Composés d'imidazoquinoxaline et leur préparation et application | |
| EP0201678B1 (fr) | 3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-méthyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazépine, son procédé de préparation et compositions pharmaceutiques | |
| EP0575442B1 (fr) | Derives d'imidazoquinazoline tetracyclique, procede de preparation et compositions pharmaceutiques les contenant | |
| US5276028A (en) | Imidazoquinoxaline compounds | |
| EP0535104B1 (fr) | Composes heterocycliques, leur preparation et utilisation | |
| US5100895A (en) | Heterocyclic compounds and their preparation and use | |
| US4866065A (en) | Imidazothienopyrimidines useful in psychopharmaceutical preparations | |
| EP0502885B1 (fr) | Composes d'imidazoquinoxaline, leur preparation et emploi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| RH | Patent void |